New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Morten Persson, Palle Damkjær Rasmussen, Jacob Madsen, Michael Ploug, Andreas Kjaer

35 Citations (Scopus)

Abstract

The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.
Original languageEnglish
JournalNuclear Medicine and Biology
Volume39
Issue number7
Pages (from-to)962-9
Number of pages8
ISSN0969-8051
DOIs
Publication statusPublished - 2012

Keywords

  • Animals
  • Beta Particles
  • Cell Transformation, Neoplastic
  • Colorectal Neoplasms
  • Dideoxynucleosides
  • Female
  • HT29 Cells
  • Heterocyclic Compounds, 1-Ring
  • Humans
  • Lutetium
  • Mice
  • Molecular Targeted Therapy
  • Neoplasm Invasiveness
  • Oligopeptides
  • Positron-Emission Tomography
  • Radioisotopes
  • Receptors, Urokinase Plasminogen Activator
  • Substrate Specificity

Fingerprint

Dive into the research topics of 'New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts'. Together they form a unique fingerprint.

Cite this